Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology

Focus On Later-Stage Prospects

 
• By Lisa Takagi
  
Takeda to terminate its pre-clinical work in AAV gene therapy and research and pre-clinical efforts in rare hematology
Takeda has recently expanded non-AAV gene therapy deals • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies